Posted on Leave a comment

Bipolar Depression Market, Size, Share, Trends, Epidemiology Forecast till 2030

Bipolar Depression Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP

DelveInsight’s “Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Bipolar Disorder, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed).

The ultimate goal of Bipolar Depression treatment is to achieve as high as possible a level of psychosocial function and health-related quality of life. BD is a highly recurrent disorder and sometimes medication needs to continue even if the patient feels well.

The treatment has two phases: the acute phase and the maintenance phase. Acute-phase treatment is focused on the management of acute mood episodes (manic, hypomanic, or depressive). Maintenance-phase treatment is focused on preventing recurrences of acute episodes. Each phase is associated with specific treatment needs, and available pharmacotherapies have shown differential effectiveness according to the illness phase.

Most commonly mood stabilizers, antipsychotics, antidepressants, antianxiety medications, and psychotherapy is used. In the United States, only four medications are approved for acute treatment of depressive episodes in the context of bipolar disorder: Symbyax (olanzapine-fluoxetine combination), Seroquel and Seroquel XR (quetiapine), Latuda (lurasidone), and Vraylar (cariprazine). Although older medications such as lithium also have modest effects in acute bipolar depression.

Bipolar Depression Market Insight

Bipolar Depression market size in 7MM in 2017 was USD 762.83 million 

Bipolar Depression Market Drivers

  • Novel insights into disease
  • Improvement in treatment over the years
  • Increasing adherence to treatment
  • Increase in awareness and advancements in the technology

Bipolar Depression Market Barriers

  • Delay in diagnosis
  • Unrecognized and inappropriate treatment
  • Neglects of quality of life, burden, and economic issues
  • Unsatisfactory design of randomized controlled trials
  • Lack of Knowledge to differentiate between unipolar and bipolar depression

Request for sample pages

Table of contents

1. Key Insights

2. Executive Summary of Bipolar Depression

3. Competitive Intelligence Analysis for Bipolar Depression

4. Bipolar Depression: Market Overview at a Glance

4.1. Bipolar Depression Total Market Share (%) Distribution in 2017

4.2. Bipolar Depression Total Market Share (%) Distribution in 2030

5. Bipolar Depression: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Bipolar Depression Pathophysiology 

5.4. Bipolar Depression Risk Factors 

5.5. Bipolar Depression Diagnosis 

6. Patient Journey

7. Bipolar Depression Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Bipolar Depression Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Bipolar Depression Epidemiology

7.4.1. Bipolar Depression Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Bipolar Depression Epidemiology

7.5.1.1. Bipolar Depression Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Bipolar Depression Epidemiology

7.5.2.1. Bipolar Depression Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Bipolar Depression Epidemiology

7.5.3.1. Bipolar Depression Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Bipolar Depression Epidemiology

7.5.4.1. Bipolar Depression Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Bipolar Depression Epidemiology

7.5.5.1. Bipolar Depression Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Bipolar Depression Epidemiology

7.5.6.1. Bipolar Depression Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Bipolar Depression Treatment and Management

8.2. Bipolar Depression Treatment Algorithm 

9. Bipolar Depression Unmet Needs

10. Key Endpoints of Bipolar Depression Treatment

11. Bipolar Depression Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Bipolar Depression Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Bipolar Depression: Seven Major Market Analysis

13.1. Key Findings

13.2. Bipolar Depression Market Size in 7MM

13.3. Bipolar Depression Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Bipolar Depression Market Size

15.1.1. Bipolar Depression Total Market Size in the United States

15.1.2. Bipolar Depression Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Bipolar Depression Market Size

15.3.1. Bipolar Depression Total Market Size in Germany

15.3.2. Bipolar Depression Market Size by Therapies in Germany

15.4. France Bipolar Depression Market Size

15.4.1. Bipolar Depression Total Market Size in France

15.4.2. Bipolar Depression Market Size by Therapies in France

15.5. Italy Bipolar Depression Market Size

15.5.1. Bipolar Depression Total Market Size in Italy

15.5.2. Bipolar Depression Market Size by Therapies in Italy

15.6. Spain Bipolar Depression Market Size

15.6.1. Bipolar Depression Total Market Size in Spain

15.6.2. Bipolar Depression Market Size by Therapies in Spain

15.7. United Kingdom Bipolar Depression Market Size

15.7.1. Bipolar Depression Total Market Size in the United Kingdom

15.7.2. Bipolar Depression Market Size by Therapies in the United Kingdom

15.8. Japan Bipolar Depression Market Outlook

15.8.1. Japan Market Size

15.8.2. Bipolar Depression Total Market Size in Japan

15.8.3. Bipolar Depression Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Bipolar Depression

17. KOL Views

18. Bipolar Depression Market Drivers

19. Bipolar Depression Market Barriers

20. Appendix

20.1. Bibliography

20.2. Bipolar Depression Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/